Amarin Corporation Plc Sponsored ADR Aktie News

The U.S. Supreme Court agreed on Friday to hear a patent dispute involving Amarin Pharma's cardiovascular drug Vascepa that could have broad consequences for generic drug makers and so-called "skinny labels" for their products that remove specific, patented uses of a brand-name medication.

DUBLIN and BRIDGEWATER, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today commented on recent innovations in therapies for patients with elevated triglycerides (TG) and shared its perspective on how these developments stand to shape patient access and treatment strategies. Specifically, ...

DUBLIN and BRIDGEWATER, N.J., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today highlighted a new post hoc analysis of aspirin use in REDUCE-IT® reinforcing that icosapent ethyl significantly reduced cardiovascular (CV) events in high-risk patients. These findings highlight the importance of guidel...

DUBLIN and BRIDGEWATER, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today announced it will be presenting new findings at the American Heart Association's Scientific Sessions 2025 scheduled for November 7-10 in New Orleans, Louisiana. These new data supported by Amarin will further reinforce ...

Amarin Corporation plc ( AMRN ) Q3 2025 Earnings Call October 29, 2025 8:00 AM EDT Company Participants Aaron Berg - CEO, President & Director Peter Fishman - Senior VP & CFO Conference Call Participants Jessica Fye - JPMorgan Chase & Co, Research Division Mazahir Alimohamed - Leerink Partners LLC, Research Division Presentation Operator Welcome to Amarin Corporation's conference call to discus...

DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, in collaboration with its Canadian partner HLS Therapeutics, a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease (CVD), announce the presen...

Amarin (AMRN) is transforming Vascepa from a declining U.S. business into a global cardiovascular growth story, driven by disciplined expense control and strategic partnerships. AMRN's European and Rest-of-World expansion, highlighted by the Recordati deal, is offsetting U.S. revenue declines and positioning the company for asset-light, high-margin growth. Restructuring is expected to yield $70...

-- Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanisms of Action -- -- Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanisms of Action --